phosphate buffered saline., FX06 clinical trials

Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0)

This study, called Ixion 2.0, is investigating a new treatment called FX06 for a severe lung condition called Acute Respiratory Distress Syndrome (ARDS). It aims to see if FX06 helps patients breathe on their own sooner compared to a dummy treatment.